Precision dosing could make stem cell transplants safer for Non-Cancer patients
NCT ID NCT05501756
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether giving a personalized dose of alemtuzumab (a drug that calms the immune system) before a stem cell transplant can improve outcomes for people with non-malignant diseases. Researchers aim to find the right dose that balances effectiveness and safety. About 60 participants will receive a tailored dose, and the study will measure whether drug levels in the blood hit a target range on transplant day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Alemtuzumab (Campath)
- What this could lead to
- If successful, this could lead to a safer, more effective way to prepare patients for stem cell transplants, reducing complications and improving recovery.
- What could go wrong
- This is a small, early-phase trial, so results may not apply to everyone. Alemtuzumab can weaken the immune system, increasing infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.